





Functional Neurological Disorder

Barbara Dworetzky, MD

Epilepsy, Brigham and Women's Hospital Professor, Harvard Medical School

Nathan Praschan, MD, MPH

Neuropsychiatry, Brigham and Women's Hospital Instructor, Harvard Medical School

UPDATE ON NEUROLOGY AND PSYCHIATRY OF WOMEN May 8, 2025

Disclosures

Dr. Dworetzky

- No relevant financial disclosures
- Founding member, BOD, President: FND Society
- Epilepsy Foundation New England, PAB
- Royalties from Oxford University Press

Dr. Praschan

No relevant financial disclosures

Objectives

Using a clinical case:

- Understand how to diagnose FND
- Know some of the brain mechanisms involved in FND
- Learn a team approach to manage/treat FND


Case: Introduction

At the time of index presentation...

- DD was a 40-year-old woman, living locally with her family, employed as group therapist at ALF
- Refractory focal epilepsy* since teens s/p TBI, MRI w/L MTS, s/p L ATL c/b cognitive sxs,个affect
- Presented to ED for ?new szs 3 wks. after surgery

*3 types of sz:1. hears voices, cluster all day 2. chewing movements LOC, 3. GTC

Course of treatment in FND




FN(S)D: Functional Neurological (Symptom) Disorder

Adapted from, Baslet et al, Clin EEG Neurosci, 2014

Getting all the History

"Listen to your patient; he/she is telling you the diagnosis." Sir William Osler



Ask "what else?"

- Listen and obtain <u>all neuro symptoms*</u>, onset, duration, frequency, warning/trigger?, recall of event? Past syncope, *panic attacks*? Unexplained ED visits?
- Build rapport (believe/show empathy, be "curious," what have others thought, what do you think?
- Identify **risk factors-** (neuro/neurosurg dx, concussion, PTSD (childhood adversity), **depression**, anxiety, **migraine**)
- Obtain social, family hx : nonjudgmental substance hx
- Do not assume psychiatric disorder or "stress"

**pain, fatigue, brain "fog" are extremely common and may need to be addressed prior to treatment

Case: New Symptoms?

At 2 mo. Post op, had episode of difficulty reading to her kids w/concern for TIA, new sz. No stroke found. At 5 mo post op, re-presented w/ frequent episodes with same prior aura.

Spell Semiology	Duration and	Triggers and	Associated
	Frequency	Warning Signs	Features
 Right-arm shaking Lip trembling Tearfulness Diffuse shaking +/- LOC 	 Seconds to minutes → up to 20 minutes Daily/ multiple daily 	 Intense emotional experiences? Same as old aura Abdominal rush sensation 	Drop attacksLimb weakness

ADMITTED TO THE EMU FOR SPELL CLARIFICATION

Case: Longitudinal History

Neurological History

Acute symptomatic GTC w/MVA at age 14 brief coma, 1 wk hospital, ("w/ wrong crowd")

Many ASMs/combos → Left ant. temp. lobect. 3/21

Since LATL, challenge w/words/memory, more emotional ("disappointments")

Psychiatric History

Episode of depression in adolescence \rightarrow near suicide attempt, no rx

Allusions to 1+ prior sexual trauma → suppression/repression, avoidant coping, longstanding low selfesteem/guilt

Active depression and anxiety since recurrence of seizures in 8/2021; but no PD, SSD/IAD, DD

General Medical and Social History

No pain or excessive fatigue

No substance use

Supportive family , limited emotional capacity, young active children

Functional Symptoms are Ubiquitous

- •Gastroenterology: IBS
- •Urology: overactive bladder syndrome
- •Rheumatology: FBM
- Infectious disease: CFS
- Immunology: multiple chemical sensitivities
- *Cardiology: Atypical CP, syncope

FN

- •*Pulmonary: Chronic cough, SOB
- •*ENT: Globus
- Gynecology: pelvic pain
- Ophthalmology: functional blindness
- Neurology: functional szs (PNES), attacks/syncope, sensory, weakness, speech, movement, cognitive disorder, and Persistent Postural-Perceptual dizziness (PPPD)


Everyone experiences functional symptoms...

Terminology

• FND is a type of *Somatic Symptom and Related Disorder*

- A. One or more symptoms of altered voluntary motor or sensory function.
- B. Clinical findings provide <u>evidence</u> of incompatibility between the symptom and recognized neurological or medical conditions.
- C. The symptom or deficit is **not explained by another** medical or mental disorder.
- D. The symptom or deficit causes **clinically significant distress or impairment** in social, occupational, or other important areas of functioning or warrants medical evaluation
- Specifier: with weakness or paralysis, with abnormal movement, with swallowing symptoms, with speech symptom, with attacks or seizures, with anesthesia or sensory loss, with special sensory symptom, dizziness, with mixed symptoms.
- Specifier: acute episode (< 6 months), persistent (> 6 months).
- Specifier: with psychological stressor, or without psychological stressor.

American Psychiatric Association, 2013 FS: Functional Seizures; FMD: Functional Movement Disorder



Epidemiology and Impact of FND

- Ann. Incid. FND: 10-22 adult, 1-18 ped/100K; min. prevalence: 80-140/100K¹
- ~30% new neuro visits "unexplained \rightarrow 18% FND²
- Seizures (sz), Motor (commonest subtypes)
- >20% have a comorbid neurological d/o (*subspecialty clinics)³
- 7.4% FS²; 5.4% syncope clinics⁴;
- Epilepsy Monitoring Unit (EMU) → 20-40% FS⁵
- Female preponderance (3:1 F:M ratio)⁶
- Adolescence \rightarrow midlife onset; *children/elderlyF=M*^{7,8}
- ↓QOL (<= other neuro disorders)⁹
- Increased risk of death (SMR 2.5x gen. pop)¹⁰⁻¹²

1.Finkelstein, et al, JNNP, 2025; 2. Stone et al, Brain 2009; 3. Stone et al, J. Neurol 2012; 4. Tannemaat et al, Neurology 2013 5. Reuber et al, Neurology 2002; 6. Lesser, Neurology, 1996; 7.Duncan et al, Neurology, 2006; 8. Huang et al, J Chin Med Assoc, 2009. 9. Karakis et al, Seizure 2014;10. Jennum et al, E and B, 2019; 11. Nightscales et al, Neurology 2020; 12. LeZhang et al, JNNP, 2022;

Case: Exam and Data

- Exam is notable w/labile affect, collapsing giveway weakness and sudden falls from an otherwise steady gait, frequent complex tics
- MRI: expected post-op changes from LATL
- vEEG:
 - In 2 days, dozens push-button events → arm shaking/flapping, eye closure, covering face with hands and rocking body, and tearfulness, lasting 20+ minutes each.
 - No electrographic correlate, only myogenic artifact

CONTEMPORARY ISSUES IN NEUROLOGIC PRACTICE

Trick or treat?

Showing patients with functional (psychogenic) motor symptoms their physical signs

- Inconsistency
- Variability
- Positive signs
- Give away weakness
- Pattern

For details on positive signs for FNDAdapted from Popkirov et al, Stroke, 2020; Syed et al, Ann Neurol, 2011; **Avbersek and Sisodiya,** JNNP 2010;







Diagnosis



'Keep your left heel on the ground – don't let me lift it up'



ift up your right leg. Don't let me push it down' LEFT hip extension returns to NORMAL

Adapted from: Stone and Edwards, Neurology 2012 tric



Ictal crying, eye closure, prolonged, memory recall, mult. types, triggers, frequent

Predisposing, precipitating and perpetuating factors




Figure 1: Pathophysiological and psychophysiological events that might trigger functional neurological disorder

The aetiology of functional neurological disorder depends on predisposing, precipitating, and perpetuating factors that affect the neural mechanisms of the disorder. The dotted line indicates that in most individuals the presence of these factors does not lead to functional neurological disorder. PTSD=post-traumatic stress disorder.

Hallett, Aybek, Dworetzky, McWhirter, Staab, Stone, Functional Neurological Disorder: New Subtypes and Shared Mechanisms, The LancetNeurology, April 2022

A Disorder of the Brain

Hallett et al, Lancet Neurology, 2022




Figure 2: Neural mechanisms of functional neurological disorder


Motor intention^{1,2,4}

Self-agency³

Connectivity between areas involved in emotion processing and motor preparation⁵

1. Marshall et al; *Cognition* 1997; 2. DeLange et al, *Neuropsychologia*, 2007; 3. Voon et al, *Neurology*, 2010; 4. Labatte et al, *Epilepsia*, 2012; 5. van der Kruijs et al, *JNNP*, 2012.

Course of treatment in FND



Adapted from, Baslet et al, Clin EEG Neurosci, 2014


Communicating the Diagnosis

ltem	Say to Patient	
Validation	common, real, not faking	
Label	Functional disorder	Lico longuago which
Diagnostic method "Do you have any que Cause & Maintaining factors	Positive features (Hoover's sign, vEEG capture) estions or concerns about what I just said? Your brain's miscommunication to the body in the context of biopsychosocial risk factors; immediate trigger often not obvious	Use language which incorporates trauma- informed-care principles*
Treatment	Effective treatments, " retrain the brain " by learning new skills	
Expectations	takes time, will improve, can resolve	

Reuber, 2003; Hall-Patch, et al Epilepsia 2010


*safety, choice, collaboration, trustworthiness, empowerment

Course of treatment in FND



Adapted from, Baslet et al, Clin EEG Neurosci, 2014

Treatment Engagement: At-risk times



Tolchin and Baslet, Treatment Adherence and Obstacles to Treatment, in Dworetzky and Baslet (Eds)"Psychogenic Non-Epileptic Seizures: Towards the Integration of Care", OUP, 2017 -- 1. Duncan et al, Epilepsy & Beh, 2014; 2. McKenzie et al, Neurology, 2010; 3. Kanner et al, Neurology, 1999; 4. LaFrance et al, JAMA Psych, 2014; 5. Baslet et al, JNCN, 2013

Patient Readiness for Treatment is Crucial

Therapy is not done to the patient- pt must "opt in" Successful outcomes depend on

- Active patient engagement
- Realistic and Specific goals for improvement
- Diagnosis agreement
- Minimizing barriers for Rehab (i.e., pain, fatigue)
- Aligning pt goals with skills of the team

Some Red Flags (patient may not be ready):

- "I will do anything to get better" yet multiple failed treatments ("help seek/help reject")
- Chronic but coping fine (no impetus for change)
- Active litigation



Case: Formulation


- Multiple experts communicated FND dx at multiple time points
- Barriers to acceptance of diagnosis
 - Comorbid, longstanding epilepsy w/ "same aura"
 - Family disbelief/limited understanding
 - Misattribution with psychiatric illness
 - Active comorbid psychiatric illness prior to and exacerbated by diagnosis: "It's my fault. I'm doing this."

Case: Formulation

- Challenging to voice concerns over fear of disappointing providers
- Exacerbating and provoking factors
 - Sensory overload
 - Boom-and-bust activity cycle
 - Dissociated self-experience: "it's not me"
 - Frustration over uncontrollable tic-like movements

Multidisciplinary team

Figure The Ideal Multidisciplinary Care Team for a Patient With FND



Adapted from O'Neal, Baslet, Polich, Raynor, Dworetzky, Functional Neurological Disorder: The Need for a Model of Care, Neurology Clin Practice, April 2021

Members of the team interact in a fluid nature as determined by the patient's needs. A neurologist may be the referring clinician or part of the multidisciplinary team.

*The Team Leader is the individual most engaged with the patient. This could be the PCP, neurologist, or one of the mental health providers.


FND = functional neurologic disorder; PCP = primary care provider.

Case: Treatment Plan

- Biopsychosocial model to address risk factors, triggers, warning signs, in a *multidisciplinary* fashion
 - Neuropsychiatry and regular epilepsy/neuro follow-up
 - Work accommodations
 - CBT for FND
 - SLP for speech symptoms/cognitive symptoms s/p ATL
 - OT for sensory overload triggers, pacing practice
 - PT for episodic weakness, bodily dissociation
- Multidisciplinary team meetings on a weekly basis
- Spousal and parental involvement, FMLA/MLOA

Educate everyone


- Safety
 - Warning signs: get to a safe spot
 - ED only for injury
 - Psychological safety: share with close family, employer as needed (including MLOA for treatment)
- Resources
 - <u>www.neurosymptoms.org</u> (UK) (FND)
 - <u>www.fndhope.org</u> (US, UK, Australia)(FND patient support website)
 - <u>www.nonepilepticseizures.com</u> (US includes info in Spanish)
 - <u>www.nonepilepticattacks.info</u> (UK)
 - https://www.fndsociety.org/fndeducation
 - Psychogenic non-epileptic seizures: A guide (Lorna Myers, Ph.D.)
 - Overcoming Functional Neurological Symptoms
 - <u>Documentary</u>: *dis-sociated* (first feature documentary on PNES) available free on YouTube <u>https://youtu.be/MA1EYAg9y5k</u>




PNES Psychogenic Non Epileptic Seizures Illuminating, Helping, Empowering.

US and other English-speaking countries. In order to achieve this, we plan to have roughly two sections: one for the PNES community (patients and loved ones) and another section for health professionals seeking reliable information and undrated on exinding reaproximation intervent. Both sections are one and can be utilitated two anunon the content of the provided sections and the patient of the content of

Home : Editorial Board : Reading materials on PNES : PNES Information : PNES Events and News : Ask us your question : Blog



Course of treatment in FND



Adapted from, Baslet et al, Clin EEG Neurosci, 2014

Case: Acute Phase

- DD engaged readily throughout treatment, attending all sessions with regularity (good patient!), but misgivings about psychiatric issues
- Often required reassurance and affirmation of correct diagnosis, although ultimately came to a deep understanding and acceptance
- Psychiatric distress remitted as acceptance grew
 - Psychiatric illness is often comorbid but distinct phenomenology and distinct treatment!
 - "Panic without panic" is a common refrain but nonetheless a different illness

Cognitive Behavioral Therapy for Dissociative Seizures




- Multicenter, RCT over 27 UK sites
- 368 adults w/ NES in prior 8 wks, no ES in 12 mos) randomized to CBT + SMC or SMC alone
- Monthly sz freq at 12 mo= primary outcome
- Secondary outcomes \rightarrow
- 75% adherent to intervention

	Estimated mean difference* (95% CI)	Standardised group difference (95% Cl)	p value
Primary outcome			
Monthly seizure frequency in last 4 weeks	NA	0·78 (0·56 to 1·09)†	0.144
Secondary outcomes			
Seizure severity score	-0·11 (-0·50 to 0·29)	-0.07 (-0.31 to 0.18)	0.593
Seizure bothersomeness severity score	-0·53 (-0·97 to -0·08)	-0·30 (-0·56 to -0·05)	0.020‡
Longest period of seizure freedom in past 6 months (days)	NA	1.64 (1.22 to 2.20)†	0.001†
Seizure freedom in last 3 months of trial	NA	1.77 (0.93 to 3.37)§	0.083
>50% reduction in monthly seizure frequency relative to baseline	NA	1·27 (0·80 to 2·02)§	0.313
Physical Component Summary score (SF-12v2)	1.78 (- 0.37 to 3.92)	0·15 (-0·03 to 0·32)	0.105
Mental Component Summary score (SF-12v2)	2·22 (-0·30 to 4·75)	0·15 (-0·03 to 0·33)	0.084
EQ-5D-5L visual analogue scale	6·16 (1·48 to 10·84)	0·27 (0·06 to 0·47)	0.010
Impact on functioning (WSAS)	-4·12 (-6·35 to -1·89)	-0·39 (-0·61 to -0·18)	<0.001
Anxiety (GAD-7)	–1·09 (–2·27 to 0·09)	-0·18 (-0·37 to 0·01)	0.069
Depression (PHQ-9)	–1·10 (–2·41 to 0·21)	-0·17 (-0·37 to 0·03)	0.099
Distress (CORE-10)	–1·65 (–2·96 to –0·35)	–0·25 (–0·45 to –0·05)	0.013‡
Other somatic symptoms (modified PHQ-15)	–1·67 (–2·90 to –0·44)	-0·26 (-0·45 to -0·07)	0.008‡
Self-reported change (CGI score)	0.66 (0.26 to 1.04)	0·39 (0·16 to 0·62)	0.001‡
Clinician-rated change (CGI score)	0·47 (0·21 to 0·73)	0·37 (0·17 to 0·57)	<0.001‡
Patient-reported satisfaction with treatment	0·90 (0·48 to 1·31)	0·50 (0·27 to 0·73)	<0.001‡

p values not adjusted for multiple testing. Standardised group differences between 0-35 and 0-65 were considered moderate. NA=not applicable. SF-12v2=12-item Short Form survey-version 2. EQ-5D-5L=EuroQoL-5 Dimensions-5 Level scale. WSAS=Work and Social Adjustment Scale. GAD-7=Generalised Anxiety Disorder seven-item. PHQ-9=Patient Health Questionnaire nine-item. CORE-10=Clinical Outcomes in Routine Evaluation-10. PHQ-15=Patient Health Questionnaire fifteen-item. CGIeClinical Global Impression. *Using original scales.†Treatment effects for count outcomes are presented as incidence rate ratios. ‡Statistically significant at 5% level (not accounting for multiple testing). STreatment effects for binary outcomes are presented as odds ratios.

Table 3: Comparison of outcome measures between the CBT plus standardised medical care and standardised medical care alone groups at 12 months derived by multiple imputation (100 imputations)

Manualized mindfulness-based psychotherapy for FS



Baslet et al, Clin EEG Neurosci, 2014

Manualized mindfulness-based psychotherapy for FS

MODULE I. UNDERSTANDING YOUR DISEASE AND YOUR TREATMENT

- Session 1: Understanding Your Illness Session 2: Identifying the function of the symptom
- Session 3: Identifying values

MODULE II: STRESS MANAGEMENT STRATEGIES

- Session 4: Understanding the stress cycle
- Session 5: Mastering a stress management skill

MODULE III: MINDFULNESS

- Session 6: Introduction to mindfulness
- Session 7: Incorporating mindfulness into everyday life

MODULE IV: EMOTION MANAGEMENT

- **Session 8: Emotion Recognition**
- Session 9: Emotion Acceptance
- Session 10: Regulation of emotion-driven behavior

MODULE V: REWORKING COGNITIONS & RELAPSE PREVENTION

- **Session 11: Reworking cognitions**
- Session 12: Relapse Prevention

I OWFR BASFI INF HYPFRAROUSAL

ASSESS COMMITMENT TO CHANGE


TRAIN THE 'PRESENT MOMENT AWARENESS' MUSCLE

USE AWARENESS TO RELATE MORE EFFECTIVELY TO THOUGHTS AND FFFI INGS

Physiotherapy in motor FND: Principles

- Limited 'hands-on' treatment. When handling the patient, facilitate rather than support.
- Encourage early weight bearing. 'On the bed strength' will not usually correlate with ability to stand in functional weakness.
- Foster independence and self-management.
- Goal directed rehabilitation focusing on function and automatic movement (eg, walking) rather than the impairment (eg, weakness) and controlled ('attention-full') movement (eg, strengthening exercises).
- Avoid use of adaptive equipment and mobility aids (though these are not always contraindicated).
- Avoid use of splints and devices that immobilize joints.
- Recognize and challenge unhelpful thoughts and behaviors.

Course of treatment in FND



Adapted from, Baslet et al, Clin EEG Neurosci, 2014

Case: Chronic Phase

Doctors don't know what to do once you have done everything you are supposed to do, and still have seixzures.

Kate Berger, "View from the floor"

- Our patient ultimately engaged in multiple courses of CBT for FND, SLP, OT, and PT
- Continued follow-up with epileptologist and neuropsychiatrist, including active pharmacotherapeutic management of psychiatric distress
- Despite consistent engagement, she remained symptomatic
 - Improvements in drop attacks
 - Persistent functional seizures
 - Near daily tic-like movements of face, arms/hands, and utterances

Case: Chronic Phase

- Nonresponse factors
 - Fear of losing providers/attachment figures
 - Ongoing psychiatric symptoms
 - Persistent boom-bust cycle of activity
 - Avoidant coping and recursive guilt over ongoing symptoms
- Chronic treatment plan
 - Address trMDD (aggressive pharmacotherapy, including ketamine)
 - Shift to DBT and trauma-focused therapy, away from FND care per se

Long-term outcomes: FS

Study	n	Method	Follow up period	Cont events in last year*	On ASM	Unemployed/ disabled	Psych morbid	Other functiona l sx's
Meierkord et al., 1991	110	Face to face	Mean 5 years	60%	n/a	20%	n/a	n/a
Selwa et al., 2000	57	Phone	19 months — 4 years	59.6%	32%, PNES only	n/a	39%	n/a
Lancman et al., 1993	63	Face to face	Mean 5 years	74.6%	n/a	n/a	n/a	n/a
Reuber et al., 2003	148	Postal	1-10 years	71.2%	40.7%, PNES only (79% cont events)	53.8%	n/a	n/a
Jones et al., 2010	61	Postal	<10 years	83%*	39%, all patients (8% with epilepsy)	n/a	52.6%	72.9%
Duncan et al., 2014	75	Postal	5-10 years	61%*	n/a	29.3% in paid employment	26.5%	n/a
Walther et al, 2019	52	Face to face	1-16 years	63%*	n/a	n/a	n/a	n/a
Asadi Pooya et al, 2018	86	Phone	4-9 years	45%*	n/a	n/a	n/a	n/a

Long-term effects of psychotherapy at 24 months - Denmark

	Inclusion	End of	Follow-u	ıp	
		treatment	12 months	24 months	
Number of participants	42	42	42	32	
Number of seizures/month	4 (1.25–11.5)	$0.75 \ \left(0-2.75 ight)^{*}$	0 (0–1) [*]	0.04 (0–2.75 [*]	
Number of patients without seizures	0	19	22	16	
>50% reduction in number of seizures	_	15	13	10	
<50% reduction in number of seizures or unchanged	_	5	4	4	
Number of patients with increased number of seizures	-	3	3	2	

Data (seizure frequency) are expressed as median with interquartile range.

* Indicates levels of significance compared with number of seizures at inclusion (p <

Table 4

 HCU before and after treatment

0.0001).

	Before	Before	After	After
	24–13	12–0	0-12	13–24
All visits	3.9	7.9	6.26	2.97
Median (IQR)	2 (1-6)	5 (4–9)	2 (1-8)	1 (0-3)
ED All causes	0.41 ± 0.79	01.51 ± 1.8	0.44 ± 0.64	0.36 ± 0.67
ED Seizures	0.15 ± 0.49	1.1 ± 1.64	0.05 ± 0.22	0.05 ± 0.32
ED Pain	0.18 ± 0.51	0.26 ± 0.55	0.28 ± 0.51	0.28 ± 0.50
ED Other	0.08 ± 0.35	0.15 ± 0.49	0.1 ± 0.31	0.08 ± 0.33
Department of Neurology	1.85 ± 2.77	3.9 ± 4.24	1.05 ± 1.73	0.54 ± 1.12
Department of Psychiatry	0.05 ± 0.22	1.18 ± 6.08	2.77 ± 10.4	0.79 ± 3.7
Other departments	1.67 ± 2.85	1.51 ± 2.27	2.54 ± 4.65	1.26 ± 2.0
Total hospital admission days (range)	60 (0-24)	119 (0-36)	97 (0-88)	28 (0–14

Number of healthcare contacts expressed as mean \pm SD, in parentheses, before and after psychotherapeutic intervention. All visits shown with mean and median IQR = interquartile range, 25th and 75th percentile. Healthcare utilization of all patients was acquired from the regional medical record system.

ED = Emergency Department

The 24-month pretreatment costs compared with the 24-month posttreatment costs directly associated with seizures dropped by 95.8%, and total healthcare costs were reduced by 63%.

Deleuran et al, Epilepsy Beh, 2019

Long-term outcomes: motor FND

24 studies (n=2069 patients)

Mean follow-up duration: 7.4 years

Overall – 40% of patients with same or worse outcome at follow-up

20% of patients with complete remission

Gelauff and Stone, Hand Clin Neurol: Funct Neurol Dis, 2016

FND-focused rehab treatment works! 13-month (median) outcome; 50% inpt - Brazil

	n (%)				
No improvement	83 (44.9%)				
Improvement	101 (55.1%) [Complete recovery of all symptoms n=39 (21.2%)]				
Rehabilitation					
No	56 (30.3%)				
Yes	129 (69.7%)				
Improvement	Rehabilitation No	Rehabilitation Yes	95%CI	chi-square p-value	
No	46	38			
Yes	10	91	11.01(4.9–23.5)	<0.0001	
	56	129			
Improvement	Age under 18 years	Age 18+	95%CI	chi-square p-value	
No	7	77		×0.0001	
Yes	40	61	7.2 (3.0–17.7)	<0.0001	

95%CI: 95% confidence interval.

Theuer et al, Arq Neuropsiqiatr, 2020

Take-home messages

- FND is common, distressing, and debilitating.
- Our understanding of FND has expanded in recent years with increasing identification of neurobiological and cognitive processing mechanisms with ongoing research.
- Evidence-based treatment for FND is growing and should be tailored to the patient in front of you (expect chronic sx).
- Ongoing communication between patient, clinicians, family, other supports is an essential part of the treatment.



FUNCTIONAL SEIZURES AND EPILEPSY:

CUTTING EDGE DIAGNOSTICS, BIOLOGY AND MANAGEMENT

JUNE 13-14, 2025

The Inn at Longwood Medical, Boston, Massachusetts

In Person, Virtual, & On-Demand





This course is endorsed by the ILAE British Branch.



Trainees can have free membership in FNDS for 1 year. To become a member: https://www.fndsociety.org/membership

Treatment in FND is multidisciplinary

Psychological interventions for psychogenic non-epileptic seizures: A meta-analysis

Perri Carlson^{*}, Kathryn Nicholson Perry

Australian College of Applied Psychology, Level 11, 255 Elizabeth Street, Sydney, NSW 2000, Australia

Occasional essay

Occupational therapy consensus recommendations for functional neurological disorder

Clare Nicholson ^(D), ¹ Mark J Edwards, ² Alan J Carson, ³ Paula Gardiner, ⁴ Dawn Golder, ⁵ Kate Hayward, ¹ Susan Humblestone, ⁶ Helen Jinadu, ⁷ Carrie Lumsden, ⁸ Julie MacLean, ⁹ Lynne Main, ¹⁰ Lindsey Macgregor, ¹¹ Glenn Nielsen, ² Louise Oakley, ¹² Jason Price, ¹³ Jessica Ranford, ⁹ Jasbir Ranu, ¹ Ed Sum, ¹⁴ Jon Stone ^(D) ³ VIEWPOINT

Physiotherapy for functional motor disorders: a consensus recommendation

Glenn Nielsen,^{1,2} Jon Stone,³ Audrey Matthews,⁴ Melanie Brown,⁴ Chris Sparkes,⁵ Ross Farmer,⁶ Lindsay Masterton,⁷ Linsey Duncan,⁷ Alisa Winters,³ Laura Daniell,³ Carrie Lumsden,⁷ Alan Carson,⁸ Anthony S David,^{9, 10} Mark Edwards¹

General neurology

Neuropsychiatry

Review

Management of functional communication, swallowing, cough and related disorders: consensus recommendations for speech and language therapy

Janet Baker, ^{1,2} Caroline Barnett, ³ Lesley Cavalli,^{4,5} Maria Dietrich, ⁶ Lorna Dixon, ⁷ Joseph R Duffy, ⁸ Annie Elias, ⁹ Diane E Fraser, ¹⁰ Jennifer L Freeburn, ¹¹ Catherine Gregory, ² Kirsty McKenzie, ¹² Nick Miller, ¹³ Jo Patterson, ¹⁴ Carole Roth, ¹⁵ Nelson Roy, ^{16,17} Jennifer Short, ¹⁸ Rene Utianski ⁽¹⁾, ^{19,20} Miriam van Mersbergen, ²¹ Anne Vertigan, ^{22,23} Alan Carson, ²⁴ Jon Stone ⁽¹⁾, ²⁴ Laura McWhirter ⁽³⁾, ²⁴

Review


Systematic review of psychotherapy for adults with functional neurological disorder

Myles Gutkin (1,2) Loyola McLean (1,2), Richard Brown (1,2), State and Richard A Kanaan (1,2)

19 studies were included

- 12 skills-based, CBT-like approaches vs 7 psychodynamic approaches
- 11 pre-post studies vs. 8 RCTs
- Most studies (except 4) included only one FND phenotype
- Effect sizes showed medium-sized benefits for physical (FND) symptoms, mental health, well-being, function and resource use for both kinds of therapies.
- Outcomes comparable across both types of therapy.
- Lack of controlled trials for psychodynamic psychotherapy.
- Lack of follow-up data in majority of CBT trials

Cognitive Behavioral Model in FND




OVECCO functional neur

CODES Cognitive Behavioral Therapy for Functional Seizures

- Multicenter, randomized controlled trial across the UK (27 sites).
- 368 adults with FS randomized to receive CBT + standardized medical care or SMC alone (2 neuro + 4 psych appts)

Standardized effects sizes at 6 and 12 months

(between arm differences)




Goldstein et al, *Lancet Psychiatry*, 2020

Changes in mean sz frequency over time


Goldstein et al, *Seizure*, 2022

Cognitive-Behavioral Therapy for FND

- Primary evidence-based treatment of FND (particularly paroxysmal)
- 2017 MA found moderate-to-• large effects benefits over treatment-as-usual; 2020 MA found similar
- What type?
 - More evidence for CBT over psychodynamic
 - Time limitations and translation to group favors CBT over psychodynamic
- Medication is not effective








Event freedom at treatment end


Affective-Inferential Model in FND



Jungilligens et al. A new science of emotion: implications for functional neurological disorder. Brain.

Mindfulness-based psychotherapy for FS

- N= 26
- 70% with 50% reduction in frequency at treatment end
- 50% with no events in last session at treatment end
- At 3- to 6-month post-tx follow-up (n=14), 93% still had lower frequency than at baseline (and 50% further improved from end of treatment).



Changes in PNES intensity and duration and in quality of life (end of treatment compared to baseline measures).

	T1 mean (SD)	T2 mean (SD)	T3 mean (SD)
PNES intensity	5.56 (2.14)	3.92 (2.69)*	3.74 (2.65)#
QOLIE-10	2.59 (0.73)	2.40 (0.76)	$2.14 (0.77)^{*}$

Statistical significant reductions from baseline scores are indicated with * for p < 0.01 and # for p < 0.05. QOLIE-10: Quality of Life in Epilepsy-10.

Baslet et al, Epilepsy and Behavior, 2020

	T1 median (min-max)	T3 median (min-max)	T3 vs. T1 max)	diff (min-	T4 median (min-max)	T4 vs. T1 di (min-max)	
Weekly frequency	1.75 (0-66.5)	0.16 (0-57.6)	-1.02 (-24	.5, 10.7)*	0.29 (0-56.0)	-1.25 (-17.5	5, 0.5)*
ТО	T1 mean (sd)	· · ·	vs. T0 diff 5%Cl)	T3 vs. T1 diff (95%Cl)	T4 mean (sd)	T4 vs. T0 diff (95%Cl)	T4 vs. T1 diff (95%Cl)
Number of days per week ^a	1.38 (0.85)	1.01 (0.84)		-0.37 (-0.69, -0.05)*	0.70 (0.68)		0.75 (-1.15, - 0.35)*
PNES intensity	5.96 (1.99)	3.74 (2.65)		-2.21 (-3.44, -0.99)'	2.92 (2.81) *		-2.94 (-4.42, - 1.46)*

Other Treatments for FND

- RCT=Randomized Controlled Trials PC=Placebo Controlled (in red, controlled interventions)
- OTHER PSYCHOLOGICAL THERAPIES (besides CBT-like and psychodynamic psychotherapy)
- Hypnosis for mixed FND (RCT)
- Brief group psychoeducation for PNES (RCT) (negative trial)¹
- Group cognitive-behavioral therapy for FS (with comorbid epilepsy)²
- Prolonged exposure for FS + PTSD³

NONINVASIVE STIMULATION-BASED THERAPIES

- rTMS over motor cortex for functional paralysis, FMD⁴⁻⁷
- rTMS over right temporo-parietal junction in FS⁸

PSYCHOPHARMACOLOGICAL THERAPIES

SSRI's (RCT for PNES, PC) (negative trial)/ SNRI's for FS and FMD

FND: Functional Neurological Disorder; FS: Functional Seizures; FMD: Functional Movement Disorders; rTMS: RepetitiveTranscranial Magnetic Stimulation.

Baslet, *Neuropsychiaric Disease and Treatment*, 2013 except 1. Chen et al, *Epilepsia*, 2014; 2. DeBarros et al, Seizure, 2018; 3. Myers et al, Epilepsy and Behavior, 2016; 4. Pick et al, 2020; 5. Taib et al, 2019; 6. Garcin et al, 2017; 7. Broersma et al, 2015; 8. Peterson et al, *Psychosomatics*, 2018;